Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders

Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to monitor hormone levels in people with adrenal disorders, such as Cushing Syndrome, Primary Aldosteronism, and Adrenal Insufficiency. The researchers aim to develop a wearable device that continuously tracks cortisol and aldosterone levels in the body. Currently, hormone testing is done only occasionally in a clinical setting, which can miss important changes over time. By using this new technology, the hope is to provide more accurate and timely information about hormone levels, making it easier to manage these conditions.

To participate in the trial, individuals must be over 18 years old and have one of the specified adrenal conditions. However, people who are pregnant, nursing, or have recently used certain medications may not be eligible. Participants can expect to wear a device that monitors their hormone levels, which could lead to better treatment options and improved health outcomes. This innovative approach aims to make hormone monitoring more accessible and comfortable, allowing patients to manage their health more effectively at home.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals (males and females) older than 18 years;
• • Patients with primary adrenal insuffiency (cortisol and aldosterone deficiency);
• • Patients with Cushing Syndrome (cortisol excess)
• • Patients with Primary Aldosteronism (aldosterone excess)
• Exclusion Criteria:
• • Use of estrogen-containing oral contraceptive medication within the past 6 weeks;
• • Pregnancy or lactation;
• • Use of oral, inhaled, parenteral, or topical glucocorticoids within the past 30 days.